Literature DB >> 195942

Substrate and effector specificity of a guanosine 3':5'-monophosphate phosphodiesterase from rat liver.

J Moss, V C Manganiello, M Vaughan.   

Abstract

Guanosine 3':5'-monophosphate phosphodiesterases, which appear to be under allosteric control, have been partially purified from rat liver supernatant and particulate fractions. The preferred substrate for both phosphodiesterases was cGMP (Km values: cGMP less than cIMP less than cAMP). At subsaturating concentrations of substrate, the phosphodiesterases were stimulated by purine cyclic nucleotides. The order of effectiveness for activation of cyclic nucleotide hydrolysis was cGMP greater than cIMP greater than cAMP greater than cXMP. Using cAMP derivatives as activators of cIMP hydrolysis, modifications in the ribose, cyclic phosphate, and purine moieties were shown to alter the ability of the cyclic nucleotide to activate the supernatant enzyme. cGMP, at concentrations that stimulated cyclic nucleotide hydrolysis, enhanced chymotryptic inactivation of the supernatant phosphodiesterase. At similar concentrations, cAMP was not effective. It appears that on interaction with appropriate cyclic nucleotides, this phosphodiesterase undergoes conformational changes that are associated with increased catalytic activity and enhanced susceptibility to proteolytic attack. Divalent cation may not be required for the nucleotide-phosphodiesterase interaction and resultant change in conformation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 195942

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Heat-stable low molecular weight form of phosphodiesterases from bovine pineal gland.

Authors:  K Sankaran; I Hanbauer; W Lovenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

Review 2.  Molecular mechanisms of go signaling.

Authors:  Meisheng Jiang; Neil S Bajpayee
Journal:  Neurosignals       Date:  2009-02-12

3.  Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver.

Authors:  N J Pyne; M E Cooper; M D Houslay
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

4.  Characterization of a rat liver cyclic GMP-activated phosphodiesterase by chromatography on hexyl-agarose. Inhibition of phosphodiesterase activity by hexyl-agarose.

Authors:  D Couchie; C Erneux; J E Dumont
Journal:  Biochem J       Date:  1981-11-01       Impact factor: 3.857

5.  Distribution of cyclic AMP phosphodiesterase in microdissected periportal and perivenous rat liver tissue with different dietary states.

Authors:  D Runge; K Jungermann
Journal:  Histochemistry       Date:  1991

6.  Atrial natriuretic factor inhibits vasopressin-stimulated osmotic water permeability in rat inner medullary collecting duct.

Authors:  H Nonoguchi; J M Sands; M A Knepper
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

7.  Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5.

Authors:  Ronald Jäger; Frank Schwede; Hans-Gottfried Genieser; Doris Koesling; Michael Russwurm
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

8.  The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding.

Authors:  Sergio E Martinez; Albert Y Wu; Natalie A Glavas; Xiao-Bo Tang; Stewart Turley; Wim G J Hol; Joseph A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

9.  Ca2+-independent cyclic GMP phosphodiesterases from rat liver and HTC hepatoma cells.

Authors:  G J Strewler; M A Danello; V C Manganiello; M Vaughan
Journal:  Biochem J       Date:  1983-08-01       Impact factor: 3.857

10.  Mathematical Modelling of Nitric Oxide/Cyclic GMP/Cyclic AMP Signalling in Platelets.

Authors:  Rune Kleppe; Inge Jonassen; Stein Ove Døskeland; Frode Selheim
Journal:  Int J Mol Sci       Date:  2018-02-19       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.